Management of multidrug-resistant Pseudomonas aeruginosa in the intensive care unit: state of the art

References

• Obritsch MD, Fish DN, MacLaren R, et al. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options. Pharmacotherapy. 2005;25:1353–1364.
   PubMed Web of Science ®Google Scholar
• Trautmann M, Lepper PM, Haller M. Ecology of Pseudomonas aeruginosa in the intensive care unit and the evolving role of water outlets as a reservoir of the organism. Am J Infect Control. 2005;33(5 Suppl 1):S41–49.
   PubMed Web of Science ®Google Scholar
• Vincent JL. Nosocomial infections in adult intensive-care units. Lancet. 2003;361:2068–2077.
   PubMed Web of Science ®Google Scholar
• Oliver A, Mulet X, López-Causapé C, et al. The increasing threat of Pseudomonas aeruginosa high-risk clones. Drug Resist Updat. 2015;21-22:41–59.
   PubMed Web of Science ®Google Scholar
• Weiner LM, Fridkin SK, Aponte-Torres Z, et al. Vital signs: preventing antibiotic-resistant infections in hospitals - United States, 2014. MMWR Morb Mortal Wkly Rep. 2016;65:235–241.
   PubMed Web of Science ®Google Scholar
• Centers for Diseases Control and Prevention. Antibiotic resistance threats in the United States, 2013. [cited 2017 Apr 15] Available from: http://www.cdc.gov/drugresistance/threat-report-2013/.
   Google Scholar
• Fothergill J, Winstanley C, James CE. Novel therapeutic strategies to counter Pseudomonas aeruginosa infections. Expert Rev. Anti Infect Ther. 2012;10:219–235.
   PubMed Web of Science ®Google Scholar
• Boucher BA, Wood GC, Swanson JM. Pharmacokinetic changes in critical illness. Crit Care Clin. 2006;22:255–271.
   PubMed Web of Science ®Google Scholar
• Roberts JA, Abdul-Aziz MH, Lipman J, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14:498–509.
   PubMed Web of Science ®Google Scholar
• Maviglia R, Nestorini R, Pennisi M. Role of old antibiotics in multidrug resistant bacterial infections. Curr Drug Targets. 2009;10:895–905.
   PubMed Web of Science ®Google Scholar
• Bergen PJ, Landersdorfer CB, Lee HJ, et al. ‘Old’ antibiotics for emerging multidrug-resistant bacteria. Curr Opin Infect Dis. 2014;25:626–633.
   Web of Science ®Google Scholar
• Gentile I, Maraolo AE, Borgia G. What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam? Expert Rev Anti Infect. Ther. 2016;14:875–878.
   PubMed Web of Science ®Google Scholar
• Kaiser SJ, Mutters NT, DeRosa A, et al. Determinants for persistence of Pseudomonas aeruginosa in hospitals: interplay between resistance, virulence and biofilm formation. Eur J Clin Microbiol Infect Dis. 2017;36:243–253.
   PubMed Web of Science ®Google Scholar
• Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Micro Rev. 2009;22:582–610.
   PubMed Web of Science ®Google Scholar
• Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis. 2002;34:634–640.
   PubMed Web of Science ®Google Scholar
• Høiby N, Ciofu O, Bjarnsholt T. Pseudomonas. In: Jh J, Ma P, editors. Manual of clinical microbiology. Washington (DC): ASM Press; 2015. p. 781–782.
   Google Scholar
• Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268–281.
   PubMed Web of Science ®Google Scholar
• Cabot G, Ocampo-Sosa AA, Domínguez MA, et al. Genetic markers of widespread extensively drug-resistant Pseudomonas aeruginosa high-risk clones. Antimicrob Agents Chemother. 2012;56:6349–6357.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics, 2017. [cited 2017 Jul 15] Available from: http://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/.
   Google Scholar
• Hirsch EB. Tam VH impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes. Expert Rev Pharmacoecon Outcomes Res. 2010;10:441–451.
   PubMed Web of Science ®Google Scholar
• Aloush V, Navon-Venezia S, Seigman-Igra Y, et al. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother. 2006;50:43–48.
   PubMed Web of Science ®Google Scholar
• Lautenbach E, Synnestvedt M, Weiner MG, et al. Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes. Infect Control Hosp Epidemiol. 2010;31:47–53.
   PubMed Web of Science ®Google Scholar
• Tam VH, Chang KT, Abdelraouf K, et al. Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010;54:1160–1164.
   PubMed Web of Science ®Google Scholar
• Morata L, Cobos-Trigueros N, Martínez JA, et al. Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother. 2012;56:4833–4837.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen XL, Huang AW, et al. Mortality attributable to carbapenem-resistant Pseudomonas aeruginosa bacteremia: a meta-analysis of cohort studies. Emerg Microbes Infect. 2016;5:e27.
   PubMed Web of Science ®Google Scholar
• Judd WR, Ratliff PD, Hickson RP, et al. Clinical and economic impact of meropenem resistance in Pseudomonas aeruginosa-infected patients. Am J Infect Control. 2016;44:1275–1279.
   PubMed Web of Science ®Google Scholar
• Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. Jama. 1995;274:639–644.
   PubMed Web of Science ®Google Scholar
• Kollef MH, Chastre J, Fagon JY, et al. Global prospective epidemiologic and surveillance study of ventilator-associated pneumonia due to Pseudomonas aeruginosa. Crit Care Med. 2014;42:2178–2187.
   PubMed Web of Science ®Google Scholar
• Melsen WG, Rovers MM, Groenwold RH, et al. Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis. 2013;13:665–671.
   PubMed Web of Science ®Google Scholar
• Rello J, Jubert P, Valles J, et al. Evaluation of outcome for intubated patients with pneumonia due to Pseudomonas aeruginosa. Clin Infect Dis. 1996;23:973–978.
   PubMed Web of Science ®Google Scholar
• El-Kholy A, Saied T, Gaber M, et al. Device-associated nosocomial infection rates in intensive care units at Cairo University hospitals: first step toward initiating surveillance programs in a resource-limited country. Am J Infect Control. 2012;40:e216–20.
   PubMed Web of Science ®Google Scholar
• Tissot F, Blanc DS, Basset P, et al. Genotyping method discovers sustained nosocomial Pseudomonas aeruginosa outbreak in an intensive care burn unit. J Hosp Infect. 2016;94:2–7.
   PubMed Web of Science ®Google Scholar
• Couto RC, Carvalho EA, Pedrosa TM, et al. A 10-year prospective surveillance of nosocomial infections in neonatal intensive care units. Am J Infect Control. 2007;35:183–189.
   PubMed Web of Science ®Google Scholar
• Blot S, Koulenti D, Dimopoulos G, et al. Prevalence, risk factors, and mortality for ventilator-associated pneumonia in middle-aged, old, and very old critically ill patients. Crit Care Med. 2014;42:601–609.
   PubMed Web of Science ®Google Scholar
• Nseir S, Di Pompeo C, Diarra M, et al. Relationship between immunosuppression and intensive care unit-acquired multidrug-resistant bacteria: a case-control study. Crit Care Med. 2007;35:1318–1323.
   PubMed Web of Science ®Google Scholar
• Harris AD, Jackson SS, Robinson G, et al. Pseudomonas aeruginosa colonization in the intensive care unit: prevalence, risk factors, and clinical outcomes. Infect Control Hosp Epidemiol. 2016;37:544–548.
   PubMed Web of Science ®Google Scholar
• Rello J, Ollendorf DA, Oster G, et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest. 2002;122:2115–2121.
   PubMed Web of Science ®Google Scholar
• Parsek MR, Singh PK. Bacterial biofilms: an emerging link to disease pathogenesis. Annu Rev Microbiol. 2003;57:677–701.
   PubMed Web of Science ®Google Scholar
• Magalhães MJ, Pontes G, Serra PT, et al. Multidrug resistant Pseudomonas aeruginosa survey in a stream receiving effluents from ineffective wastewater hospital plants. BMC Microbiol. 2016;16:193.
   PubMed Web of Science ®Google Scholar
• Guy M, Vanhems P, Dananché C, et al. Outbreak of pulmonary Pseudomonas aeruginosa and Stenotrophomonas maltophilia infections related to contaminated bronchoscope suction valves, Lyon, France, 2014. Euro Surveill. 2016;21:30286.
   Google Scholar
• Cobos-Trigueros N, Solé M, et al. Acquisition of Pseudomonas aeruginosa and its resistance phenotypes in critically ill medical patients: role of colonization pressure and antibiotic exposure. Crit Care. 2015;19:218.
   PubMed Web of Science ®Google Scholar
• Venier AG, Leroyer C, Slekovec C, et al. Risk factors for Pseudomonas aeruginosa acquisition in intensive care units: a prospective multicentre study. J Hosp Infect. 2014;88:103–108.
   PubMed Web of Science ®Google Scholar
• El Amari EB, Chamot E, Auckenthaler R, et al. Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin Infect Dis. 2001;33:1859–1864.
   PubMed Web of Science ®Google Scholar
• Warburton DW, Bowen B, Konkle A. The survival and recovery of Pseudomonas aeruginosa and its effect upon salmonellae in water: methodology to test bottled water in Canada. Can J Microbiol. 1994;40:987–992.
   PubMed Web of Science ®Google Scholar
• Deplano A, Denis O, Poirel L, et al. Molecular characterization of an epidemic clone of panantibiotic-resistant Pseudomonas aeruginosa. J Clin Microbiol. 2005;43:1198–1204.
   PubMed Web of Science ®Google Scholar
• Halwani M, Solaymani-Dodaran M, Grundmann H, et al. Cross-transmission of nosocomial pathogens in an adult intensive care unit: incidence and risk factors. J Hosp Infect. 2006;63:39–46.
   PubMed Web of Science ®Google Scholar
• Meyer E, Jonas D, Schwab F, et al. Design of a surveillance system of antibiotic use and bacterial resistance in German intensive care units (SARI). Infection. 2003;31:208–215.
   PubMed Web of Science ®Google Scholar
• Bonten MJM, Bergmans DC, Speijer H, et al. Characteristics of polyclonal endemicity of colonization in intensive care units. Implications for infection control. Am J Respir Crit Care Med. 1999;160:1212–1219.
   PubMed Web of Science ®Google Scholar
• Mayank D, Anshuman M, Singh RK, et al. Nosocomial cross-transmission of Pseudomonas aeruginosa between patients in a tertiary intensive care unit. Indian J Pathol Microbiol. 2009;52:509–513.
   PubMed Web of Science ®Google Scholar
• Agodi A, Barchitta M, Cipresso R, et al. Pseudomonas aeruginosa carriage, colonization, and infection in ICU patients. Intensive Care Med. 2007;33(7):1155–1161.
   PubMed Web of Science ®Google Scholar
• Grundmann H, Barwolff S, Tami A, et al. How many infections are caused by patient-to-patient transmission in intensive care units? Crit Care Med. 2005;33:946–951.
   PubMed Web of Science ®Google Scholar
• Buhl M, Peter S, Willmann M. Prevalence and risk factors associated with colonization and infection of extensively drug-resistant Pseudomonas aeruginosa: a systematic review. Expert Rev Anti Infect Ther. 2015;13:1159–1170.
   PubMed Web of Science ®Google Scholar
• Boyer A, Doussau A, Thiébault R, et al. Pseudomonas aeruginosa acquisition on an intensive care unit: relationship between antibiotic selective pressure and patients’ environment. Crit Care. 2011;15:R55.
   PubMed Web of Science ®Google Scholar
• Tacconelli E, Cataldo MA, Dancer SJ, et al. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect. 2014;20(Suppl 1):1–55.
   PubMed Web of Science ®Google Scholar
• Wisplinghoff M, Seifert H. Pseudomonas aeruginosa. In: Bearman GML, Stevens M, Edmond MB, et al., editors. A guide to infection control in the hospital. Boston (MA): International Society for Infectious Diseases; 2014. p. 323–326.
   Google Scholar
• Vincent JL. Vaccine development and passive immunization for Pseudomonas aeruginosa in critically ill patients: a clinical update. Future Microbiol. 2014;9:457–463.
   PubMed Web of Science ®Google Scholar
• Johansen HK, Gøtzsche PC. Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst Rev. 2015;8:CD001399.
   Google Scholar
• Rello J, Krenn CG, Locker G, et al. A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients. Crit Care. 2017;21:22.
   PubMed Web of Science ®Google Scholar
• Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet. 2005;44:1009–1034.
   PubMed Web of Science ®Google Scholar
• Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009;37:840–851.
   PubMed Web of Science ®Google Scholar
• De Rosa FG, Corcione S, Baietto L, et al. Pharmacokinetics of linezolid during extracorporeal membrane oxygenation. Int J Antimicrob Agents. 2013;41:590–591.
   PubMed Web of Science ®Google Scholar
• De Rosa FG, Corcione S, Baietto L, et al. Pharmacokinetics of anidulafungin in two critically ill patients with septic shock undergoing CVVH. J Chemother. 2013;25:376–378.
   PubMed Web of Science ®Google Scholar
• Padkin A, Goldfrad C, Brady AR, et al. Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland. Crit Care Med. 2003;31:2332–2338.
   PubMed Web of Science ®Google Scholar
• Ostermann M, Chang RW. Acute kidney injury in the intensive care unit according to RIFLE. Crit Care Med. 2007;35:1837–1843.
   PubMed Web of Science ®Google Scholar
• Kramer L, Jordan B, Druml W, et al. Incidence and prognosis of early hepatic dysfunction in critically ill patients–a prospective multicenter study. Crit Care Med. 2007;35:1099–1104.
   PubMed Web of Science ®Google Scholar
• Smith BS, Yogaratnam D, Levasseur-Franklin KE, et al. Introduction to drug pharmacokinetics in the critically ill patient. Chest. 2012;141:1327–1336.
   PubMed Web of Science ®Google Scholar
• Roberts DJ, Hall RI. Drug absorption, distribution, metabolism and excretion considerations in critically ill adults. Expert Opin Drug Metab Toxicol. 2013;9:1067–1084.
   PubMed Web of Science ®Google Scholar
• Parker SL, Sime FB, Roberts JA. Optimizing dosing of antibiotics in critically ill patients. Curr Opin Infect Dis. 2015;28:497–504.
   PubMed Web of Science ®Google Scholar
• Blot SI, Pea F, Lipman J. The effect of pathophysiology on pharmacokinetics in the critically ill patient-concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev. 2014;77:3–11.
   PubMed Web of Science ®Google Scholar
• Udy AA, Roberts JA, Lipman J. Clinical implications of antibiotic pharmacokinetic principles in the critically ill. Intensive Care Med. 2013;39:2070–2082.
   PubMed Web of Science ®Google Scholar
• Taccone FS, Cotton F, Roisin S, et al. Optimal meropenem concentrations to treat multidrug-resistant pseudomonas aeruginosa septic shock. Antimicrob Agents Chemother. 2012;56:2129–2131.
   PubMed Web of Science ®Google Scholar
• Labreche MJ, Graber CJ, Nguyen HM. Recent updates on the role of pharmacokinetics-pharmacodynamics in antimicrobial susceptibility testing as applied to clinical practice. Clin Infec Dis. 2015;61:1446–1452.
   PubMed Web of Science ®Google Scholar
• Scaglione F. Can we transfer pharmacokinetics/pharmacodynamics of antimicrobials into clinical practice. Int J Antimicrob Agents. 2015;46(Suppl 1):S40–S42.
   PubMed Web of Science ®Google Scholar
• Wong G, Sime FB, Lipman J, et al. How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients? BMC Infect Dis. 2014;14:288.
   PubMed Web of Science ®Google Scholar
• Roberts JA, Lipman J. Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility. Crit Care Med. 2013;41:489–495.
   PubMed Web of Science ®Google Scholar
• Traugott KA, Echevarria K, Maxwell P, et al. Monotherapy or combination therapy? The Pseudomonas aeruginosa conundrum. Pharmacotherapy. 2011;31:598–608.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Villa G, Pecori D. Antibiotic-resistant Pseudomonas aeruginosa: focus on care in patients receiving assisted ventilation. Future Microbiol. 2014;9:465–474.
   PubMed Web of Science ®Google Scholar
• Acar JF. Antibiotic synergy and antagonism. Med Clin North Am. 2000;84:1391–1406.
   PubMed Web of Science ®Google Scholar
• Paul M, Leibovici L. Editorial commentary: combination therapy for Pseudomonas aeruginosa bacteremia: where do we stand? Clin Infect Dis. 2013;57:217–220.
   PubMed Web of Science ®Google Scholar
• Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev. 2012;25:450–470.
   PubMed Web of Science ®Google Scholar
• Hu Y, Li L, Li W, et al. Combination antibiotic therapy versus monotherapy for Pseudomonas aeruginosa bacteraemia: a meta-analysis of retrospective and prospective studies. Int J Antimicrob Agents. 2013;42:492–496.
   PubMed Web of Science ®Google Scholar
• Vardakas KZ, Tansarli GS, Bliziotis IA, et al. β-Lactam plus aminoglycoside or fluoroquinolone combination versus β-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis. Int J Antimicrob Agents. 2013;41:301–310.
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, Sa-Borges M, Sole-Violan J, et al. Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med. 2007;35:1888–1895.
   PubMed Web of Science ®Google Scholar
• Kollef KE, Schramm GE, Wills AR, et al. Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria. Chest. 2008;134:281–287.
   PubMed Web of Science ®Google Scholar
• Micek ST, Reichley RM, Kollef MH, et al. Health care-associated pneumonia (HCAP): empirical antibiotics targeting methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa predict optimal outcome. Medicine (Baltimore). 2011;90:390–395.
   PubMed Web of Science ®Google Scholar
• Peña C, Gómez-Zorrilla S, Oriol I, et al. Impact of multidrug resistance on Pseudomonas aeruginosa ventilator-associated pneumonia outcome: predictors of early and crude mortality. Eur J Clin Microbiol Infect Dis. 2013;32:413–420.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, De Pascale G, Trecarichi EM, et al. Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients. Intensive Care Med. 2013;39:682–692.
   PubMed Web of Science ®Google Scholar
• Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63:61–111.
   PubMed Web of Science ®Google Scholar
• Micek ST, Lloyd AE, Ritchie DJ, et al. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother. 2005;49:1306–1311.
   PubMed Web of Science ®Google Scholar
• Bowers DR, Liew YX, Lye DC, et al. Outcomes of appropriate empirical combination versus monotherapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother. 2013;57:1270–1274.
   PubMed Web of Science ®Google Scholar
• Peña C, Suarez C, Ocampo-Sosa A, et al. Effect of adequate single-drug vs combination antimicrobial therapy on mortality in Pseudomonas aeruginosa bloodstream infections: a post hoc analysis of a prospective cohort. Clin Infect Dis. 2013;57:208–216.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Carnelutti A, Peghin M. Patient specific risk stratification for antimicrobial resistance and possible treatment strategies in gram-negative bacterial infections. Expert Rev Anti Infect Ther. 2017;15:55–65.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Chung P, Adam HL, et al. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs. 2014;74:31–51.
   PubMed Web of Science ®Google Scholar
• Castanheira M, Mills JC, Farrell DJ, et al. Mutation-driven β-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from U.S. hospitals. Antimicrob Agents Chemother. 2014;58:6844–6850.
   PubMed Web of Science ®Google Scholar
• Cabot G, Bruchmann S, Mulet X, et al. Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC. Antimicrob Agents Chemother. 2014;58: 3091–3099.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Bassetti M, Duncan LR, et al. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15). J Antimicrob Chemother. 2017;72:1386–1395.
   PubMed Web of Science ®Google Scholar
• Castón JJ, Á DLT, Ruiz-Camps I, et al. Salvage therapy with ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections. Antimicrob Agents Chemother. 2017;61:e02136–16.
   PubMed Web of Science ®Google Scholar
• Oliver WD, Heil EL, Gonzales JP, et al. Ceftolozane-tazobactam pharmacokinetics in a critically Ill patient on continuous venovenous hemofiltration. Antimicrob Agents Chemother. 2015;60:1899–1901.
   PubMed Web of Science ®Google Scholar
• Van Duin D, Bonomo RA. Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation β-lactam/β-lactamase inhibitor combinations. Clin Infect Dis. 2016;63:234–241.
   PubMed Web of Science ®Google Scholar
• Sader HS, Huband MD, Castanheira M, et al. Pseudomonas aeruginosa antimicrobial susceptibility results from four years (2012 to 2015) of the international network for optimal resistance monitoring program in the United States. Antimicrob Agents Chemother. 2017;61(3):e02252–16.
   PubMed Web of Science ®Google Scholar
• Buyck JM, Luyckx C, Muccioli GG, et al. Pharmacodynamics of ceftazidime/avibactam against extracellular and intracellular forms of Pseudomonas aeruginosa. J Antimicrob Chemother. 2017; 72: 1400-09 Neuner EA, Gallagher JC. Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae. Virulence. 2016;9:1–13.
   Google Scholar
• Roberts JA, Webb S, Paterson D, et al. A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics. Crit Care Med. 2009;37:2071–2078.
   PubMed Web of Science ®Google Scholar
• Taccone FS, Laterre PF, Dugernier T, et al. Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care. 2010;14:R126.
   PubMed Web of Science ®Google Scholar
• Osthoff M, Siegemund M, Balestra G, et al. Prolonged administration of β-lactam antibiotics - a comprehensive review and critical appraisal. Swiss Med Wkly. 2016;146:w14368.
   PubMed Web of Science ®Google Scholar
• Roberts JA, Abdul-Aziz MH, Davis JS, et al. Continuous versus intermittent β-lactam infusion in severe sepsis. A meta-analysis of individual patient data from randomized trials. Am J Respir Crit Care Med. 2016;194:681–691.
   PubMed Web of Science ®Google Scholar
• Taccone FS, Laupland KB, Montravers P. Continuous infusion of β-lactam antibiotics for all critically ill patients? Intensive Care Med. 2016;42:1604–1606.
   PubMed Web of Science ®Google Scholar
• Bauer KA, West JE, O’Brien JM, et al. Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections. Antimicrob Agents Chemother. 2013;57:2907–2912.
   PubMed Web of Science ®Google Scholar
• Yost RJ, Cappelletty DM. The retrospective cohort of extended-infusion piperacillin-tazobactam (RECEIPT) study: a multicenter study. Pharmacotherapy. 2011;31:767–775.
   PubMed Web of Science ®Google Scholar
• Cb L, Nation RL. Colistin: how should it be dosed for the critically ill? Semin Respir Crit Care Med. 2015;36:126–135.
   PubMed Web of Science ®Google Scholar
• Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 55:3284–3294.
   PubMed Web of Science ®Google Scholar
• Corcione S, Baietto L, Malvasio V, et al. Pharmacokinetics of colistin methanesulfonate (CMS) in burn patients. J Antimicrob Chemother. 2017;72:319–321.
   PubMed Web of Science ®Google Scholar
• Karnik ND, Sridharan K, Jadhav SP, et al. Pharmacokinetics of colistin in critically ill patients with multidrug-resistant Gram-negative bacilli infection. Eur J Clin Pharmacol. 2013;69:1429–1436.
   PubMed Web of Science ®Google Scholar
• Lu Q, Luo R, Bodin L, et al. Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Anesthesiology. 2012;117:1335–1347.
   PubMed Web of Science ®Google Scholar
• Lin YW, Zhou QT, Cheah SE, et al. Pharmacokinetics/pharmacodynamics of pulmonary delivery of colistin against pseudomonas aeruginosa in a mouse lung infection model. Antimicrob Agents Chemother. 2017;61:e02025–16.
   PubMed Web of Science ®Google Scholar
• Kunakonvichaya B, Thirapanmethee K, Khuntayaporn P, et al. Synergistic effects of fosfomycin and carbapenems against carbapenem-resistant Pseudomonas aeruginosa clinical isolates. Int J Antimicrob Agents. 2015;45:556–557.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Vouloumanou EK, Samonis G, et al. Fosfomycin. Clin Microbiol Rev. 2016;29:321–347.
   PubMed Web of Science ®Google Scholar
• Asuphon O, Montakantikul P, Houngsaitong J, et al. Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic/pharmacodynamic (PK/PD) simulation. Int J Infect Dis. 2016;50:23–29.
   PubMed Web of Science ®Google Scholar
• Krause KM, Serio AW, Kane TR, et al. Aminoglycosides: an overview. Cold Spring Harb Perspect Med. 2016;6:a027029.
   PubMed Web of Science ®Google Scholar
• Roger C, Nucci B, Molinari N, et al. Standard dosing of amikacin and gentamicin in critically ill patients results in variable and subtherapeutic concentrations. Int J Antimicrob Agents. 2015;46:21–27.
   PubMed Web of Science ®Google Scholar
• Solé-Lleonart C, Rouby JJ, Blot S, et al. Nebulization of antiinfective agents in invasively mechanically ventilated adults: a systematic review and meta-analysis. Anesthesiology. 2017;126:890–908.
   PubMed Web of Science ®Google Scholar
• Kanj SS, Kanafani ZA. Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc. 2011;86:250–259.
   PubMed Web of Science ®Google Scholar
• Szałek E, Tomczak H, Kamińska A, et al. Pharmacokinetics and pharmacodynamics of ciprofloxacin in critically ill patients after the first intravenous administration of 400 mg. Adv Med Sci. 2012;57:217–223.
   PubMed Web of Science ®Google Scholar
• El Solh AA, Alhajhusain A. Update on the treatment of Pseudomonas aeruginosa pneumonia. J Antimicrob Chemother. 2009;64:229–238.
   PubMed Web of Science ®Google Scholar
• Zilahi G, McMahon MA, Povoa P, et al. Duration of antibiotic therapy in the intensive care unit. J Thorac Dis. 2016;8:3774–3780.
   PubMed Web of Science ®Google Scholar
• Goodlet KJ, Nicolau DP, Nailor MD. Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections. Ther Clin Risk Manag. 2016;12:1811–1826.
   PubMed Web of Science ®Google Scholar
• Prabhu V, Foo J, Ahir H, et al. Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK. J Med Econ. 2017;8:1–10.
   Google Scholar